WO2002051425A1 - Remedes pour l'hepatite c - Google Patents
Remedes pour l'hepatite c Download PDFInfo
- Publication number
- WO2002051425A1 WO2002051425A1 PCT/JP2001/011365 JP0111365W WO02051425A1 WO 2002051425 A1 WO2002051425 A1 WO 2002051425A1 JP 0111365 W JP0111365 W JP 0111365W WO 02051425 A1 WO02051425 A1 WO 02051425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluoro
- deoxy
- group
- resin
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Definitions
- the present invention relates to a therapeutic agent for hepatitis C, and more particularly, to a 3,3-dexoxy-3′-fluorouridine derivative having a specific structure and 1 -(3'-deoxy-3'-fluoro-j3-L-lipofuranosyl) ⁇ Hepatitis C treated with a lacyl derivative as an active ingredient About remedies.
- Background art
- HCV hepatitis C virus
- HCV is a flavivirus that has a single-stranded RNA of + strand as a genome, and is a virus that grows by RNA-dependent RNA polymerase. .
- RNA-dependent RNA polymerase By inhibiting this RNA-dependent RNA polymerase of HCV specifically but not by inhibiting human RNA polymerase, the proliferation of HCV can be reduced. Still, it may pave the way for effective treatment of hepatitis C. However, no effective inhibitors have yet been found.
- the inventors of the present invention have conducted intensive studies to provide an excellent therapeutic agent for hepatitis C with few side effects, and as a result, have found that 3'-doxy-3'-fluoropolymer Inducer and 1- (3'-doxy-3, -fluoro- / 3-L-lipofuranosyl) ⁇
- the lacyl conductor is a human RNA polymerase.
- HCV RNA-dependent RNA polymerase has a selective enzyme inhibitory activity without inhibiting the enzyme. It has been reached.
- R is a hydrogen atom, an octagen atom, an alkyl group, a halogen-substituted alkyl group, a hydroxyalkyl group, an aminoalkyl group, It represents an amino group, a holmyl group, a cyano group, or an unsubstituted or modified benzyl group.
- Z represents a carbon atom or a nitrogen atom, and when Z represents a carbon atom, R 2 represents a hydrogen atom, a halogen atom, a holmyl group or a cyano group.
- R q is a hydroxyl group or a formula
- n 1, 2 or 3
- Y independently represents an oxygen atom or a sulfur atom.
- Therapeutic agent for hepatitis C the following general formula ( ⁇ )
- R is a hydrogen atom, a halogen atom, an alkyl group, a halogen-substituted alkyl group, a hydroxyalkyl group, or an alkyl group. It represents a aminoalkyl group, an amino group, a formyl group, a cyano group, or an unsubstituted or modified benzyl group.
- Z represents a carbon atom or a nitrogen atom, and when Z represents a carbon atom, R 2 represents a hydrogen atom, a halogen atom, a holmyl group or a cyano group.
- q is a hydroxyl group or formula
- X and Y each represent an oxygen atom or a sulfur atom.
- 1- (3, -deoxy-3'_fluoro-// 3-L-libofuranosyl) represented by the formula: ⁇ lasil derivative, its salt and its A compound selected from these hydrates or solvates; and a therapeutic agent for hepatitis C containing the compound as an active ingredient.
- Fig. 1 shows the HCV genomic detection limits of the sample to which the compound of Synthesis Example 1 was added, the sample to which the compound of Synthesis Example 2 was added, and the sample to which the compound of the present invention was not added.
- the electrophoresis photograph showing the "dilution degree (fold)” and the “total RNA amount in cells (ng)" are shown.
- Figure 2 shows the HCV genomic analysis of a sample to which the compound of Synthesis Example 10 was added, a sample to which the compound of Synthesis Example 11 was added, and a sample to which the compound of the present invention was not added.
- An electrophoretic photograph showing the “limit of dilution (fold)” and “total RNA content of cells (/ Ig)” are shown.
- Best mode for carrying out the invention Examples of the compound of the present invention include compounds represented by the following general formula (I) and the following general formula (II).
- R i is a hydrogen atom, a halogen atom, an alkyl group, a halogen-substituted alkyl group, or a hydrogen atom.
- You. z is the carbon source When Z denotes a carbon atom, R represents a child or nitrogen atom;
- the no and the halogen atoms include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and the like.
- the alkyl group include an alkyl group having 1 to 6 carbon atoms, preferably a methyl group, an ethyl group, or a normal propyl group. Or an alkyl group having 1 to 3 carbon atoms such as an isopropyl group; and the aminoaminoalkyl group is 4-amino.
- Examples include a butyl group, a 3-aminopropyl group, a 2-aminoethyl group or an aminomethyl group.
- Examples of the modifying group for the benzyl group include a halogen atom, an alkyl group, a halogen-substituted alkyl group, a hydroxyalkyl group, and an amino group. Examples include an alkyl group, an amino group, a formyl group, a cyano group, and the like, examples of which are as described above.
- R 3 is a hydroxyl group or a formula
- lacyl derivatives include, for example, the following compounds.
- 3'-dexoxy-3, -fluorinated derivatives represented by the above general formula (I), which are the active ingredients in the present invention 3, -Doxy-3'-Fluoro resin, 3'-Doxy -5, 3'-Difluoro resin, 3, -Doxy - 3'-Fluoro-5-methylpyridine is obtained from Hemant K. Misraeta 1., J. Heterocyclic Chem., 21, 773 (1984)., Noyori et al. No. 62-81 1397), L. Alder eta 1., Biochemical and Environmental Mass Spectrometry, Vol. 13, 217-221 (1986), A.
- 1- (3, -dexoxy-3,3-fluoro- ⁇ -L-lipofuranosilile) represented by the above general formula ( ⁇ ) Is an enantiomer L of the above-mentioned known compound D, and can be produced by converting a sugar raw material into L-xylose according to the information. .
- the 3, -dexi-3'-fluorofluorinated derivative represented by the above general formula (I) and the 1-(-) represented by the above general formula ( ⁇ ) 3'-deoxy — 3'-fluoro—] 3—L—libofuranosyl) Peracyl derivatives are formed into physiologically acceptable salts be able to .
- the salt include an Alkali metal salt, an Alkaline earth metal salt, an ammonium salt, and an alkylammonium salt. You can do it.
- 8-L-lipofuranosyl) ⁇ lacyl derivatives and their salts may optionally be added to their Can be formed into hydrates or solvates Wear .
- solvates include methanol, ethanol, isoprono, and the like. Knol, acetate, ethyl acetate, methylene chloride, etc. can be mentioned.
- the 3′-dexoxy-3, -fluorouridine derivative represented by the above general formula (I) and the 1- (3 ′) represented by the above general formula ( ⁇ ) -Deoxy-3, -Fluoro mouth -j3-L—Ribofuranosyl) Persil derivative has antiviral, anti-RNA viral, anti-C It is an anti-hepatitis drug having a hepatitis C virus action and can be used as a therapeutic agent for hepatitis C.
- the therapeutic agent for hepatitis C of the present invention may use the above-mentioned active ingredient itself as it is, but may use a general-purpose pharmaceutical additive to prepare a pharmaceutical composition containing the above-mentioned active ingredient. It is preferred that they be manufactured and used.
- Examples of the dosage form of the pharmaceutical composition include tablets, capsules, fine granules, pills, lozenges, liquids, injections, suppositories, ointments, patches, and the like. Can be used. They can be given orally (including sublingually) or parenterally.
- Oral pharmaceutical compositions can be manufactured by conventional, general-purpose methods such as mixing, filling or tableting. Further, the active ingredient may be distributed in a pharmaceutical composition using a large amount of filler by using a repetitive combination operation.
- tablets or capsules intended for oral administration are preferably provided as unit dosages, which include binders, fillers, and diluents. It may contain commonly used preparation carriers such as tablets, tablets, lubricants, disintegrants, coloring agents, flavoring agents or wetting agents. Tablets may be prepared according to methods well known in the art, for example, using a coating. — Can be tent tablets.
- Preferred fillers include cellulose, mannitol or lactose.
- starch derivatives such as starch, polyvinylpyrrolidone, and sodium starch glycolate are used.
- disintegrants such as sodium perylyl sulfate, and the like.
- compositions in the form of oral liquids include, for example, aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs. And dry pharmaceutical compositions that can be redissolved in water or a suitable vehicle before use.
- Such liquids may contain the usual additives, such as, for example, sorbitol, syrup, methyl, aluminum stearate or gel.
- Precipitating agents such as hydrogenated edible fats; emulsifiers such as lecithin, sorbitan monooleate or arabia gum; armor oil Oil fractions such as coconut oil or glycerin ester from rectified fractions; propylene glycol or ethyl alcohol; Nonaqueous media (which may also include edible oils); p-hydroxybenzoic acid methyl ester, ethyl ester or propyl ester. Or a preservative such as sorbic acid; and, if necessary, a usual flavoring or coloring agent. In ⁇ You can.
- compositions suitable for parenteral administration include liquid pharmaceutical compositions, suppositories and patches containing the above-mentioned active ingredients and a sterilizing medium.
- the active ingredient can be suspended, dissolved or emulsified depending on the medium and concentration.
- a non-porous solution composition can It is preferably manufactured by dissolving the active ingredient in a vehicle, sterile-filtering, then filling and sealing the appropriate vial or sample. it can .
- the aqueous composition may be adjusted, and then the water may be removed by freeze-drying.
- Parenteral suspensions are prepared in substantially the same manner as the parenteral solution compositions described above, but, for example, the active ingredient may be suspended in the vehicle. It can be manufactured by sterilizing using an ethylene oxide, etc., and then suspending in a sterilizing medium. In the manufacture of a suspension or the like, a surfactant or a wetting agent may be added, if necessary, so that the active ingredient is uniformly distributed in the preparation.
- Pharmaceutical compositions in other forms can also be manufactured by methods known to those skilled in the art. The form and manufacturing method of a pharmaceutical composition which is one embodiment of the medicament of the present invention are described below. It is not limited to the above.
- the oral pharmaceutical composition (for example, in the case of tablets, capsules, fine granules, etc.) usually contains 5 to 95% by weight, preferably 25 to 90% by weight.
- a parenteral pharmaceutical composition (for example, for an injection) containing the active ingredient of the formula (1) is usually 0.5 to 20% by weight, preferably 1 to 10% by weight. Contains active ingredients.
- the therapeutic agent of the present invention is useful for the treatment of HCV-induced hepatitis.
- the dosage of the therapeutic agent of the present invention depends on the patient's age, health condition, body weight, severity of the disease, type and frequency of treatment / treatment performed at the same time, and the nature of the desired effect. It should be decided more appropriately.
- the dose per adult is 0.01 to 5 O mg / kg body weight, preferably 1 to 30 mg / kg body weight of the active ingredient. Therefore, it may be administered once or several times a day.
- Example 2 The 3, -dexoxy-5,3'-difluoroolefin used in Example 2 below was prepared according to the synthesis example of J. Med. Chem. 34, 2195 (1991). It was manufactured.
- the reaction system was poured into cold water, extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated to obtain a residue of 80 mg. This was dissolved in 1 M ammonia in ethanol, and the mixture was stirred at room temperature for 120 hours. The reaction system was concentrated and washed with getyl cellulose to obtain the title compound (21 mg).
- a target compound was obtained in the same manner as in Synthesis Example 2 except that 5-methyl peroxyl was used in place of 5-fluorosilyl.
- a target compound was obtained in the same manner as in Synthesis Example 2 except that 5-trifluoromethyl peryl was used instead of 5-fluoropropyl.
- a target compound was obtained in the same manner as in Synthesis Example 2 except that 5-mouracil was used in place of 5-fluorosilyl. '
- the target compound was obtained in the same manner as in Synthesis Example 2 except that 6-azizatacil was used instead of 5-fluorosilyl.
- the target compound was obtained in the same manner as in Synthesis Example 2 except that 2-thioperacil was used instead of 5 _ fluorosilyl.
- the reaction system was poured into cold water, extracted with ethyl acetate, dried over magnesium sulfate, filtered, and concentrated to give a residue of 159 mg.
- the residue was purified by silica gel chromatography and purified by chromatography to obtain 119 mg. This was dissolved in 1 M ammonium hydroxide in methanol and stirred at room temperature for 15 hours. The reaction system was concentrated and washed with diethyl ether to obtain the title compound (16 mg).
- HCV RNA polymerase Expression and purification of HCV RNA polymerase was performed according to a known method (V. Lohman et al., VIROLOGY, 249, 108-118, 1998).
- the inhibitory ability of the compounds of Synthesis Example 12, Synthesis Example 13, Synthesis Example 19, Synthesis Example 21 and Synthesis Example 22 was determined by the HCV RNA polymerase. It was expressed as the 50% inhibition concentration when the negative control without the enzyme was 0% and the positive control without the compound was 100%. Table 1>
- composition example 12 3 'one te', one oxy, three fluorescein 5, five triphosphate 0.3 (composition example 12)
- the activity of the anti-HCV growth inhibition activity was measured according to a known method (Kato, N. et. A. Biocliem. Biophs. Res. Commun. 206, 863-869, 1995). It was.
- Cultured MT-2C cells (1 ⁇ 10 6 cells) were fed with EDTA (ethylenamine 4-acetic acid) to give a final concentration of 5 ⁇ in F- ⁇ 2 medium (Gibco- BL 11059 -0 29)
- the cells were suspended in 200 u1 and infected with hepatitis C serum 201 for 2 hours at 37 ° C. After infection, wash three times with 1 ml of PBS (Phosphate buf fe red saline), suspend in 6 ml of RPMI medium containing 10% of FBS, and spread on a 48 we 11 culture plate.
- reverse transcription reaction was performed at 37 ° C for 1 hour at a total volume of 20 ul, followed by reverse transcription enzyme inactivation at 100 at 30 minutes.
- the reverse transcriptase is Super Scrip T MII (Gibco BRL 18064-014)
- the primer is HCVJ strain (Ka to, N. et. A 1. Pro Natl. Acad. Sc i USA 87, 9524-9528, 1990), a 20-base 01 igoDNA (Gico BRL) complementary to the base sequence from base number 317 to base number 336 was used.
- Reverse transcription reaction product is sterilized.3 times with distilled water.10 times.30 times.1
- nucleotides of the sequence of nucleotides 71 and 90 of the strain 01 i goDNA (Gibco BRL) and 20 nucleotides 01 igoDNA (Gibco BRL) complementary to the sequence from base number 317 to base number 336 were used.
- the secondary PCR reaction (94 ° C for 1 minute, 58 ° C for 45 seconds, 72 ° C for 1 minute for 34 cycles, 94 ° C) C 1 minute, 58 ° C 1 minute 40 seconds, 72 ° C 8 minutes 1 cycle).
- EX-Taa (TAKARA) as a DNA synthase
- HCV- as a primer
- [20-base ol igoDNA (Gibco BRL) having a sequence from base number 122 to 141 of the strain
- a complementary 20-base oligoDNA (Gibco BRL) was used for the sequence from base numbers 246 to 265.
- the secondary PCR reaction product 51 was electrophoresed on a 3% agarose gel and stained with ethidium bromide to detect a DNA fragment.
- HCV genome was detected in the negative control samples 1) and 2) containing no compound up to 30-fold or 100-fold dilution.
- 0.1 M was added for the sample to which the compound of Synthesis Example 1 was added.
- samples 3) and 4 the sample was added 10-fold or 30-fold, and 1.0 M was added.
- the HCV genome was not detected at up to 3 or 10 times in the added samples 5) and 6), and up to 3 or 3 times in 10) added samples 7) and 8). It was found that the limit of detection dilution decreased with the concentration of the compound.
- the negative control samples 1), 2), 3) and 4) containing no compound were HCV genomics diluted 10-fold or 30-fold. Can be detected, whereas the sample containing the compound of Synthesis Example 10 was added 1 ⁇ M, and one sample was added 5), 6), and 10 ⁇ m added sample 7), 8) Samples containing the compound of Example 1 (1 ⁇ l), 10 ⁇ l of each of the added samples (9), 10), and 10 / M (1) and 12) were diluted 10-fold. Except for one sample, the HCV genome was not detected. At this time, since the total RNA yield of each sample was hardly changed, these compounds did not harm the cells and were found in the cells. Was considered to be inhibiting the growth of HCV. Industrial applicability
- an excellent therapeutic agent for hepatitis C which has a small side effect and is intended for the treatment of hepatitis C caused by HCV.
- This application is filed with Japanese Patent Application No. 200-0 — 394 620, Japanese Patent Application No. 200-1 — 234 542, and Japanese Patent Application No. 200-101. The application was filed with priority claim of No. 585.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002552568A JPWO2002051425A1 (ja) | 2000-12-26 | 2001-12-25 | C型肝炎治療剤 |
EP01271879A EP1346724A4 (en) | 2000-12-26 | 2001-12-25 | REMEDIES FOR HEPATITIS C |
CA002437209A CA2437209A1 (en) | 2000-12-26 | 2001-12-25 | Remedies for hepatitis c |
US10/465,931 US20040063651A1 (en) | 2000-12-26 | 2001-12-25 | Remedies for hepatitis c |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000/394620 | 2000-12-26 | ||
JP2000394620 | 2000-12-26 | ||
JP2001/23542 | 2001-01-31 | ||
JP2001023542 | 2001-01-31 | ||
JP2001/105585 | 2001-04-04 | ||
JP2001105585 | 2001-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002051425A1 true WO2002051425A1 (fr) | 2002-07-04 |
Family
ID=27345541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/011365 WO2002051425A1 (fr) | 2000-12-26 | 2001-12-25 | Remedes pour l'hepatite c |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040063651A1 (ja) |
EP (1) | EP1346724A4 (ja) |
JP (1) | JPWO2002051425A1 (ja) |
CN (1) | CN1482914A (ja) |
CA (1) | CA2437209A1 (ja) |
WO (1) | WO2002051425A1 (ja) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005080388A1 (en) | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2005123087A2 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
WO2006012078A2 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
WO2008085508A2 (en) | 2007-01-05 | 2008-07-17 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US7666855B2 (en) | 2004-02-13 | 2010-02-23 | Metabasis Therapeutics, Inc. | 2′-C-methyl nucleoside derivatives |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
WO2010084115A2 (en) | 2009-01-20 | 2010-07-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Antiviral agents |
US7767660B2 (en) | 2006-12-20 | 2010-08-03 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7781422B2 (en) | 2006-12-20 | 2010-08-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2011014882A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
US7973040B2 (en) | 2008-07-22 | 2011-07-05 | Merck Sharp & Dohme Corp. | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
US7989438B2 (en) | 2007-07-17 | 2011-08-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Therapeutic compounds |
US8101595B2 (en) | 2006-12-20 | 2012-01-24 | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA | Antiviral indoles |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8178520B2 (en) | 2006-05-15 | 2012-05-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic compounds as antiviral agents |
US8216999B2 (en) | 2005-07-20 | 2012-07-10 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8314062B2 (en) | 2006-06-23 | 2012-11-20 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8377873B2 (en) | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
WO2014123794A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014123795A2 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
JP2016530313A (ja) * | 2013-09-11 | 2016-09-29 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
US9738661B2 (en) | 2006-10-27 | 2017-08-22 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
JP7508501B2 (ja) | 2013-09-11 | 2024-07-01 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20160119A1 (es) | 2013-05-16 | 2016-02-24 | Riboscience Llc | Derivados de nucleosido 4'-azido, 3'-desoxi-3'-fluoro sustituido |
US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
WO2016145142A1 (en) * | 2015-03-10 | 2016-09-15 | Emory University | Nucleotide and nucleoside therapeutics compositions and uses related thereto |
WO2017106710A1 (en) * | 2015-12-17 | 2017-06-22 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0296590A (ja) * | 1988-09-30 | 1990-04-09 | Asahi Glass Co Ltd | 新規核酸類 |
WO2001060315A2 (en) * | 2000-02-18 | 2001-08-23 | Shire Biochem Inc. | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0780897B2 (ja) * | 1985-10-04 | 1995-08-30 | 旭硝子株式会社 | リボフラノシド誘導体の製造法 |
JPS62242624A (ja) * | 1986-04-15 | 1987-10-23 | Asahi Glass Co Ltd | 抗腫瘍剤 |
US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
-
2001
- 2001-12-25 CA CA002437209A patent/CA2437209A1/en not_active Abandoned
- 2001-12-25 EP EP01271879A patent/EP1346724A4/en not_active Withdrawn
- 2001-12-25 US US10/465,931 patent/US20040063651A1/en not_active Abandoned
- 2001-12-25 CN CNA018213839A patent/CN1482914A/zh active Pending
- 2001-12-25 JP JP2002552568A patent/JPWO2002051425A1/ja active Pending
- 2001-12-25 WO PCT/JP2001/011365 patent/WO2002051425A1/ja not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0296590A (ja) * | 1988-09-30 | 1990-04-09 | Asahi Glass Co Ltd | 新規核酸類 |
WO2001060315A2 (en) * | 2000-02-18 | 2001-08-23 | Shire Biochem Inc. | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS [online] accession no. STN Database accession no. 112:69447 * |
See also references of EP1346724A4 * |
VANAERSCHOT A. ET AL: "Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-spectrum antiviral activity of3'-fluoro-3'-deoxyadenosine", ANTIVIRAL RES., vol. 12, no. 3, 1989, pages 133 - 150, XP002908279 * |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666855B2 (en) | 2004-02-13 | 2010-02-23 | Metabasis Therapeutics, Inc. | 2′-C-methyl nucleoside derivatives |
EP2626354A1 (en) | 2004-02-20 | 2013-08-14 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
WO2005080388A1 (en) | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2005123087A2 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
WO2006012078A2 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8216999B2 (en) | 2005-07-20 | 2012-07-10 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8178520B2 (en) | 2006-05-15 | 2012-05-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic compounds as antiviral agents |
US8314062B2 (en) | 2006-06-23 | 2012-11-20 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8377873B2 (en) | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US9738661B2 (en) | 2006-10-27 | 2017-08-22 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7781422B2 (en) | 2006-12-20 | 2010-08-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US7767660B2 (en) | 2006-12-20 | 2010-08-03 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
US8101595B2 (en) | 2006-12-20 | 2012-01-24 | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA | Antiviral indoles |
WO2008085508A2 (en) | 2007-01-05 | 2008-07-17 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US7989438B2 (en) | 2007-07-17 | 2011-08-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Therapeutic compounds |
US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
EP2540349A1 (en) | 2008-07-22 | 2013-01-02 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitor |
US8080654B2 (en) | 2008-07-22 | 2011-12-20 | Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
US7973040B2 (en) | 2008-07-22 | 2011-07-05 | Merck Sharp & Dohme Corp. | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
EP2540350A1 (en) | 2008-07-22 | 2013-01-02 | Merck Sharp & Dohme Corp. | Combinations of a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitors with other HCV agents |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
WO2010084115A2 (en) | 2009-01-20 | 2010-07-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Antiviral agents |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
WO2011014882A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
WO2014123795A2 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014123794A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
JP2016530313A (ja) * | 2013-09-11 | 2016-09-29 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
JP2022081641A (ja) * | 2013-09-11 | 2022-05-31 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
JP7508501B2 (ja) | 2013-09-11 | 2024-07-01 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
Also Published As
Publication number | Publication date |
---|---|
EP1346724A4 (en) | 2004-11-17 |
JPWO2002051425A1 (ja) | 2004-04-22 |
US20040063651A1 (en) | 2004-04-01 |
CN1482914A (zh) | 2004-03-17 |
CA2437209A1 (en) | 2002-07-04 |
EP1346724A1 (en) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002051425A1 (fr) | Remedes pour l'hepatite c | |
JP6355605B2 (ja) | N−[(2’r)−2’−デオキシ−2’−フルオロ−2’−メチル−p−フェニル−5’−ウリジリル]−l−アラニン1−メチルエチルエステルおよびその製造のためのプロセス | |
EP2227482B1 (en) | 2',4'-substituted nucleosides as antiviral agents | |
JP4980059B2 (ja) | 抗ウイルスヌクレオシド類似体およびウイルス感染特にhiv感染の処置方法 | |
EP1707571B1 (en) | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | |
KR20120138242A (ko) | 뉴클레오사이드 포스포르아미데이트 | |
JP2018531227A6 (ja) | アレナウイルス科およびコロナウイルス科のウイルス感染を処置するための方法 | |
JP2018531227A (ja) | アレナウイルス科およびコロナウイルス科のウイルス感染を処置するための方法 | |
MX2013013570A (es) | Profarmacos de monofosfato de purina para el tratamiento de infecciones virales. | |
IL201239A (en) | Phosphoramide Nucleuside Compounds | |
JP2008517912A (ja) | RNA依存性RNAウイルス感染治療用フッ素化ピロロ[2,3−d]ピリミジンヌクレオシド | |
JP2003532643A (ja) | 肝炎ウイルス感染症を治療するための3’−または2’−ヒドロキシメチル置換ヌクレオシド誘導体 | |
JPH03504969A (ja) | ピリミジン誘導体 | |
TW201605885A (zh) | 尿嘧啶核苷酸類似物及其製備方法和應用 | |
JP2017523224A (ja) | ネプラノシンaの1’,6’−異性体の鏡像体 | |
KR970011386B1 (ko) | 1-(2'-데옥시-2'-플루오로-베타-d-아리비노-푸라노실)-5-에틸우라실을 이용한 간염 비루스 감염질환의 치료방법 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001271879 Country of ref document: EP Ref document number: 2002552568 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018213839 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2437209 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10465931 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001271879 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001271879 Country of ref document: EP |